Ester Orlandi

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients.

Mario Lazzarino, Ester Orlandi, Marco Paulli et al. · Journal of Clinical Oncology · 1997 · 176 citations

Medicine, Oncology, Chemotherapy +13

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Simona Soverini, Alessandra Gnani, Sabrina Colarossi et al. · Blood · 2009 · 174 citations · Full text

Medicine, Genetics, Oncology +16

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Soverini, Caterina De Benedittis, Cristina Papayannidis et al. · Cancer · 2013 · 143 citations · Full text

Medicine, Hematology, Oncology +16

Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles

Luca Arcaini, Marco Paulli, Emanuela Boveri et al. · Cancer · 2003 · 132 citations · Full text

Medicine, Oncology, Pathology +17